Manages hypertension. ANDA 74673, held by Epic Pharma LLC. Guanfacine Hydrochloride.
As of Nov 16, 2026, ANDA 74673 (Guanfacine Hydrochloride), held by Epic Pharma LLC, was first approved by FDA on Feb 28, 1997, with 4 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Guanfacine hydrochloride tablets are indicated in the management of hypertension. Guanfacine may be given alone or in combination with other antihypertensive agents, especially thiazide-type diuretics.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Feb 28, 1997 | Original application | Approved | None posted |
| Guanfacine HydrochlorideEQ 1MG BASE · tablet;oral | Guanfacine Hydrochloride | Rx |
| Guanfacine HydrochlorideEQ 2MG BASE · tablet;oral | Guanfacine Hydrochloride | Rx |
| May 6, 2015 | Supplement 11Labeling · Standard review | Approved | None posted |
| May 6, 2015 | Supplement 8Labeling | Approved | None posted |
| Nov 12, 2002 | Supplement 2Labeling | Approved | None posted |
| Oct 4, 1999 | Supplement 1Manufacturing | Approved | None posted |
| Feb 28, 1997 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters